A study of switching from Remicade to a biosimilar shows mixed results:
https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz070/5446199
Excerpt:
"Conclusions
Switching from Remicade to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. Nocebo effect might have influenced this result. Switching from Remicade to CT-P13 was safe."
https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz070/5446199
Excerpt:
"Conclusions
Switching from Remicade to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. Nocebo effect might have influenced this result. Switching from Remicade to CT-P13 was safe."